Home › Brands › Cronos Group
⚐ Flag an error How this page was made
Also known as: Cronos Group Inc. · CRON

Cronos Group

Toronto-based public cannabis company with Altria as largest shareholder, selling adult-use and CBD products.

Automated fact-check pass
10 cited sources
Published
Last reviewed
How this page was made
↯ The honest take

Cronos is a real, publicly traded LP with significant U.S. tobacco money behind it—but that hasn't insulated it from the Canadian cannabis market downturn or regulatory mishaps. It's restated financials, faced SEC action, and written down assets like most peers. Check current filings before believing revenue claims; the Spinach brand is widely stocked, but that doesn't mean every product is high-quality or consistent.

What it is

Cronos Group Inc. is a publicly traded cannabis company headquartered in Toronto, Ontario, trading on the Toronto Stock Exchange and Nasdaq under ticker CRON [1][2]. It operates as a federally licensed producer under Canada's Cannabis Act, selling adult-use cannabis products in Canada, CBD products in the United States, and limited medical cannabis activity internationally [1]. The company was originally incorporated as PharmaCan Capital Corp. in 2012 and rebranded to Cronos Group in 2016 [1].

Ownership and corporate structure

Cronos is publicly traded but heavily influenced by its largest shareholder, Altria Group (the U.S. tobacco conglomerate that owns Philip Morris USA). In March 2019, Altria completed a C$2.4 billion investment giving it approximately 45% equity stake in Cronos along with warrants [3][4]. As of recent filings, Altria remains the largest shareholder, though exact percentages and warrant status vary; readers should verify against current SEC 10-K/40-F and SEDAR+ filings for the most accurate ownership breakdown [1][2]. Cronos's subsidiaries have included Cronos USA (holder of the Lord Jones CBD brand) and production entities tied to its PEACE NATURALS facility in Stayner, Ontario [1].

Market focus and products

Cronos's primary revenue stream is the Canadian adult-use market, where it sells dried flower, pre-rolls, vapes, edibles, and concentrates [1]. The company also sells CBD products in the United States through the Lord Jones brand. Historically, Cronos has pursued medical cannabis and export arrangements in jurisdictions including Israel, Germany, and Australia, though the current scope and status of these operations should be verified against recent quarterly filings [1].

Cronos has invested in cannabinoid research, including a partnership with Ginkgo Bioworks aimed at producing cultured cannabinoids through fermentation; however, the commercial output of this program has been limited, and the agreement was restructured in 2021 [5].

Consumer brands:

Note: this is a description of the brand portfolio, not a recommendation. Product availability, formulations, and quality vary by SKU and batch; verify current Certificates of Analysis and provincial retailer listings.

Regulatory issues and controversies

Cronos has faced significant public regulatory and financial challenges:

Accounting restatement and SEC settlement: In 2021, Cronos restated previously issued financial statements for 2019 and interim 2020 periods after identifying issues with revenue recognition related to bulk resin transactions [8]. In October 2022, the U.S. Securities and Exchange Commission announced a settled action against Cronos; the company agreed to a cease-and-desist order without admitting or denying the SEC's findings [9]. A former executive was separately charged in connection with these issues Strong evidence[9].

Asset impairments: Like other Canadian licensed producers, Cronos has recorded substantial goodwill and asset write-downs since 2019 as the Canadian cannabis market underperformed post-legalization projections; these are disclosed in annual 10-K and 40-F filings [1][2].

Strategic restructuring: Cronos has scaled back facilities and restructured its U.S. and international operations over time. Older press releases and investor presentations should not be treated as current operational descriptions.

Availability and legal status

Canada: Cronos's adult-use products (primarily Spinach) are sold through provincial wholesalers and licensed retailers; availability varies by province and product. PEACE NATURALS medical cannabis is sold directly to registered medical patients under Health Canada's framework [6].

United States: Lord Jones CBD products are sold in the U.S. market under the regulatory environment following the 2018 Farm Bill, which legalized hemp-derived CBD federally but left product-specific FDA status unresolved [10]. The FDA has not approved CBD as a dietary supplement or for most therapeutic claims Strong evidence[10].

International: Cronos has held medical cannabis licenses or export arrangements in various jurisdictions; current status varies and should be checked against the company's most recent quarterly or annual filing before assuming active operations [1].

What to verify before relying on Cronos claims

Before treating any Cronos marketing statement or investor claim as fact:

  1. Current ownership and Altria stake — check the latest 10-K, 40-F, and proxy filings on SEC EDGAR and SEDAR+ [1][2].
  2. Licensing status — verify PEACE NATURALS and other production sites against Health Canada's current list of licensed cultivators and sellers.
  3. Product specifics — cannabinoid content, terpene profiles, and contaminant testing should come from the current batch Certificate of Analysis, not marketing materials or older documentation.
  4. Financial and operational claims — revenue figures, market share, and capacity statements should be verified against the most recent quarterly or annual regulatory filing, not press releases.
  5. Health or wellness claims — for Lord Jones or any other CBD product, note that the FDA has not approved CBD as a dietary supplement or medication for most claimed benefits Strong evidence[10].

Last verified: October 2026. Cannabis companies and their licensing, ownership, and product portfolios change frequently; treat any information older than the current quarter as potentially stale.

Sources

  1. Government U.S. Securities and Exchange Commission. Cronos Group Inc. Form 10-K filings (EDGAR database).
  2. Government System for Electronic Document Analysis and Retrieval Plus (SEDAR+). Cronos Group Inc. filings.
  3. Reported Bray, C. (2018). Altria to Take 45% Stake in Cannabis Company Cronos Group. The New York Times, December 7, 2018.
  4. Reported Maloney, J. (2019). Altria Closes $1.8 Billion Investment in Cannabis Company Cronos. The Wall Street Journal, March 8, 2019.
  5. Reported Israel, S. (2021). Cronos Group, Ginkgo Bioworks restructure cannabinoid production deal. MJBizDaily, September 2021.
  6. Government Ontario Cannabis Store (OCS). Product catalogue and retail listings.
  7. Reported Crowe, P. (2019). Cronos Group buys CBD brand Lord Jones for $300 million. Reuters, August 2019.
  8. Reported Israel, S. (2021). Cronos Group restates 2019, early 2020 financials over revenue recognition. MJBizDaily.
  9. Government U.S. Securities and Exchange Commission. SEC Charges Cronos Group with Accounting Fraud. Press Release 2022-189, October 24, 2022.
  10. Government U.S. Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD).

How this page was made

Generation history

Oct 31, 2026
Fact-check pass — raised 3 flags
Oct 31, 2026
Revision
Jun 8, 2026
Fact-check pass — raised 2 flags
Jun 8, 2026
Initial draft

Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.